Increased excretion of dimethyltryptamine and certain features of psychosis: a possible association.

The excretion of the hallucinogen dimethyltryptamine (DMT) and its precursor N-methyltryptamine (NMT) was studied among 74 recently admitted psychiatric patients and 19 normal persons. Both compounds were detected in 24-hour urine samples from all subjects. Dimethyltryptamine excretion was greatest in schizophrenia, mania, and "other psychosis" and tended to decline as clinical state improved. Psychotic depressives excreted smaller amounts of DMT more akin to those excreted by neurotic and normal subjects. Urinary NMT excretion was unrelated to psychiatric diagnosis. Ratings on the Present State Examination (PSE) also indicated that increased excretion of DMT was associated with psychotic rather than neurotic psychopathology. Forty-three percent of the variance in urinary DMT levels could be explained in terms of six of the 38 PSE syndromes. Syndromes suggesting elation, perceptual abnormalities, and difficulty in thinking and communicating were most correlated with raised urinary DMT excretion.

[1]  R. Rodnight,et al.  A gas chromatographic procedure for determining N, N-dimethyltryptamine and N-monomethyltryptamine in urine using a nitrogen detector. , 1977, Biochemical medicine.

[2]  D. Stoff,et al.  Dose response and time course effects of N,N-dimethyltryptamine on disruption of rat shuttlebox avoidance. , 1977, Biological psychiatry.

[3]  R. Murray,et al.  Urinary dimethyltryptamine and psychiatric symptomatology and classification , 1977, Psychological Medicine.

[4]  D. Murphy,et al.  Monoamine Oxidase in Chronic Schizophrenia , 1977, British Journal of Psychiatry.

[5]  R. Prasad,et al.  The biosynthesis of dimethyltryptamine in vivo. , 1977, Research communications in chemical pathology and pharmacology.

[6]  R. Rodnight,et al.  Mass spectrometric identification of N-monomethyltryptamine following incubation of tryptamine with brain protein and S-adenosylmethionine or 5-methytetrahydrofolic acid. , 1976, Biochemical pharmacology.

[7]  A. Dittrich,et al.  Eine experimentelle Untersuchung zur bewußtseinsverändernden Wirkung von N,N-Dimethyltryptamin (DMT) , 1976 .

[8]  E. Domino,et al.  Effects of N,N-dimethyltryptamine on electrically evoked responses in the cat visual system and modification by neuroleptic agents , 1976, Neuropharmacology.

[9]  E. Domino,et al.  Effects of iproniazid and tranylcypromine of the half-life of N,N-dimethyltryptamine in rat brain and liver. , 1976, Biochemical pharmacology.

[10]  R. Wyatt,et al.  The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine. , 1976, The American journal of psychiatry.

[11]  M. Jarvik,et al.  The effects of hallucinogens on blind monkeys. , 1976, International pharmacopsychiatry.

[12]  H. Rosengarten,et al.  A review of recent studies of the biosynthesis and excretion of hallucinogens formed by methylation of neurotransmitters or related substances. , 1976, Schizophrenia bulletin.

[13]  H. Meltzer,et al.  Neuromuscular dysfunction in schizophrenia. , 1976, Schizophrenia bulletin.

[14]  W. Carpenter,et al.  A test of the transmethylation hypothesis in acute schizophrenic patients. , 1975, The American journal of psychiatry.

[15]  R. Priest.  Measurement and Classification of Psychiatric Symptoms , 1975 .

[16]  R. Wyatt,et al.  N,N-dimethyltryptamine--a possible relationship to schizophrenia? , 1974, Advances in biochemical psychopharmacology.

[17]  D. Murphy,et al.  Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. , 1972, The American journal of psychiatry.

[18]  W. Vandenheuvel,et al.  Indoleamine-N-methyl transferase in human lung. , 1972, Biochemical pharmacology.

[19]  J. Axelrod,et al.  Psychotomimetic N-Methylated Tryptamines: Formation in Brain in vivo and in vitro , 1972, Science.